<DOC>
	<DOC>NCT00541866</DOC>
	<brief_summary>This study will evaluate the safety and tolerability of voreloxin injection in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.</brief_summary>
	<brief_title>Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans</brief_title>
	<detailed_description>Other objectives of this study include: 1. Assess antileukemic activity 2. Characterize the pharmacokinetic profile 3. Evaluate potential biomarkers</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Relapsed or refractory AML subtypes, except acute promyelocytic leukemia (APL) History of myocardial infarction within 3 months of study treatment History of cerebrovascular accident/transient ischemic attack (CVA/TIA) within 3 months of study treatment Thromboembolic event (deep vein thrombosis or pulmonary embolus) within 28 days of study treatment Known intolerance to cytarabine or known allergy to Dsorbitol or methanesulfonic acid Please note: There are additional inclusion/exclusion criteria for this study. Please contact the study center for additional information and to determine if all study criteria are met.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Myeloid</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Cancer</keyword>
	<keyword>AML</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>SNS-595</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Voreloxin</keyword>
</DOC>